ABSTRACT
Background Recently, we have identified a dysregulated protein signature in the esophageal epithelium of eosinophilic esophagitis (EoE) patients; however, the effect of proton pump inhibitor (PPI) treatment on this signature is unknown. Herein, we used a proteomic approach to investigate: (1) whether PPI treatment alters the esophageal epithelium protein profile observed in EoE patients and (2) whether the protein signature at baseline predicts PPI response.
Methods We evaluated the protein signature of esophageal biopsies using a cohort of adult EoE (n=25) patients and healthy controls (C) (n=10). In EoE patients, esophageal biopsies were taken before (Pre) and after (Post) an 8-week PPI treatment, determining the histologic response. Eosinophil count PostPPI was used to classify the patients: ≥15 eosinophils/hpf as non-responders (NR) and <15 eosinophils/hpf as responders (R). Protein signature was determined and differentially accumulated proteins (DAP) were characterized to identify altered biological processes and signaling pathways.
Results High dimensional analysis of DAP between groups revealed common signatures between three groups of patients with inflammation (R-PrePPI, NR-PrePPI and NR-PostPPI) and without inflammation (C and R- PostPPI). PPI therapy almost reversed the EoE specific esophageal protein signature, which is enriched in pathways associated with inflammation and epithelial barrier function, in R-PostPPI. Furthermore, we identified a set of candidate proteins to differentiate R-PrePPI and NR-PrePPI EoE patients before treatment.
Conclusion These findings provide evidence that PPI therapy reverses the alterations in the protein profile associated with EoE. Interestingly, our results also suggest that PPI response could be predicted at baseline in EoE.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Finantial support: PM and CS are supported by grants PI17/0008 and ISCIII-Proteored 2019 of Instituto de Salud Carlos III (ISCIII, Spain) and co-funded by Fondo Europeo de Desarrollo Regional (FEDER). CS is also funded by Asociacion Espanola de Gastroenterologia (AEG) 2019 grant. JM is supported by grant PID2021-123144OB-I00 funded by MCIN /AEI /10.13039/501100011033 / FEDER, UE. LU-T is recipient of an INVESTIGO contract from Comunidad de Madrid (09-PIN1-00015.6/2022) partly funded by the European Social Fund, NextGenerationEU, and Recovery, Transformation and Resilience Plan. CR-R is recipient of an INVESTIGO contract from Ministry of Labour and Social Economy, the national public employment service (SEPE) (INVESTIGO Exp. 2022‐C23.I01.P03. S0020‐0000031) partly funded by the European Social Fund, NextGenerationEU, and Recovery, Transformation and Resilience Plan. EJL-M holds a Juan Rodes grant (JR19/00005) from the ISCIII, Spanish Ministry of Health - Social Services and Equality, which is partly funded by the European Social Fund (2014-2020).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Research Ethics Committee of Instituto de Investigacion Sanitaria Hospital Universitario de La Princesa (registry number 3107, 8 June 2017). All patients and controls signed an informed consent form before sampling. All necessary patient/participant consent has been obtained. Any patient/participant/sample identifiers cannot be used to identify individuals.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵& Senior author
Data availability statement
The data that supports the findings of this study are available in the supplementary material of this article. Additional dataset will be available upon request at time on publication. Please contact the corresponding author for any inquiries.
Abbreviations
- C
- Control
- DAP
- Differentially accumulated proteins.
- DEG
- Differentially expressed genes
- EDP
- EoE diagnostic panel
- EoE
- Eosinophilic esophagitis
- GERD
- Gastroesophageal reflux disease
- GO
- Gene ontology (GO) terms
- hpf
- High-power field
- IPA
- Ingenuity Pathway Analysis
- NR-PostPPi
- Patient with EoE Non-Responder to PPI post-treatment
- NR-PrePPi
- Patient with EoE Non-Responder to PPI pre-treatment
- PCA
- Principal component analysis
- PPI
- Proton pump inhibitors
- PPI-REE
- Proton pump inhibitor-responsive esophageal eosinophilia
- RNAseq
- RNA sequencing
- R-PostPPi
- Patient with EoE Responder to PPI post-treatment
- R-PrePPi
- Patient with EoE Responder to PPI pre-treatment
